Residual malignant cells

Residual malignant cells" is not the standardized name for a therapeutic molecular target, receptor, or protein. Instead, this term collectively describes cancer cells that remain in the body after cancer treatment, such as surgery, chemotherapy, or radiation[2][3][1]. These cells are not a single molecule or protein but refer to a heterogeneous population of **tumor cells** that survive initial therapy and may lead to cancer relapse if not eliminated. The clinical concept of **minimal residual disease (MRD)** is used to describe this phenomenon; MRD refers to these residual cells or their molecular traces (such as circulating tumor DNA) that persist undetectably by imaging but can be identified with sensitive assays[2][1][3]. In research and therapy, MRD is monitored as a risk factor for recurrence and used to guide post-treatment clinical decisions[1][3]. Some studies focus on the unique biology of **residual tumor cells**, especially in locations such as the margins after surgical resection in solid tumors like glioblastoma, where these cells may have different properties than the main tumor mass[4]. However, "residual malignant cells" is not a protein, receptor, or druggable gene product per se, but a descriptive category encompassing any remaining malignant cell population after therapy. Because this is not a molecular entity, it has no specific molecular abbreviation, definitive interacting drugs, or a mechanism of action for targeted therapies as would a receptor or enzyme. Relapse prevention strategies target these populations through a variety of mechanisms depending on the original cancer type—such as cytotoxic agents, kinase inhibitors, or immunotherapies. Detection relies on markers like ctDNA or cancer-specific antigens, but these are determined by the context of the underlying malignancy, not by a universal marker for "residual malignant cells"[1][2][3]. In summary, "residual malignant cells" is a clinical and pathologic concept, not a defined molecular target, and should not be treated as a canonical single molecule or receptor in structured drug-target databases.

Other names

minimal residual diseasemolecular residual diseasemeasurable residual diseaseresidual tumor cells